Ticker >

Strides Pharma Scien share price

Strides Pharma Science Ltd.

NSE: STAR BSE: 532531 SECTOR: Pharmaceuticals & Drugs  58k   112   25

849.90
+10.40 (1.24%)
NSE: Today, 10:34 AM

Price Summary

Today's High

₹ 852.8

Today's Low

₹ 839.5

52 Week High

₹ 865

52 Week Low

₹ 306.9

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

7810.56 Cr.

Enterprise Value

9074.18 Cr.

No. of Shares

9.19 Cr.

P/E

105.23

P/B

2.21

Face Value

₹ 10

Div. Yield

0.18 %

Book Value (TTM)

₹  384.4

CASH

85.58 Cr.

DEBT

1349.2 Cr.

Promoter Holding

27.39 %

EPS (TTM)

₹  8.08

Sales Growth

-6.29%

ROE

0.14 %

ROCE

1.56%

Profit Growth

-97.4 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-6.29%
3 Year3.11%
5 Year4.76%

Profit Growth

1 Year-97.4%
3 Year-66.11%
5 Year-65%

ROE%

1 Year0.14%
3 Year2.67%
5 Year3.07%

ROCE %

1 Year1.56%
3 Year2.7%
5 Year3.48%

Debt/Equity

0.3927

Price to Cash Flow

32.31

Interest Cover Ratio

0.533032405070593

CFO/PAT (5 Yr. Avg.)

0.842555670506936

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 27.39 69.17
Sep 2023 27.78 67.4
Jun 2023 28.07 80.8
Mar 2023 28.27 81.8
Dec 2022 30.89 69.44
Investors List
* Figures given above are % of equity capital

 Strengths

 Looks like the company does not have any notable strengths.

 Limitations

  • The company has shown a poor profit growth of -66.1089247369439% for the Past 3 years.
  • The company has shown a poor revenue growth of 3.10527051237677% for the Past 3 years.
  • Company has a poor ROE of 2.66814970910606% over the past 3 years.
  • Company has a poor ROCE of 2.69805723793694% over the past 3 years
  • Company has low Interest coverage ratio of 0.533032405070593.
  • Company has high debtor days of 256.267948272738.
  • Company has contingent liabilities of 1313.04 Cr.
  • The company is trading at a high PE of 105.23.
  • Promoter pledging is high as 69.17%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 386.51 563.56 475.32 540.29 520.02
Total Expenditure 340.91 444.12 419.76 497.02 454.36
Operating Profit 45.61 119.44 55.56 43.27 65.65
Other Income 29.75 26.38 11.65 22.34 8.69
Interest 35.1 42.9 36.63 40.07 44.47
Depreciation 22.26 22.71 21.46 21.34 21.06
Exceptional Items 0 -15 0 0 -5.29
Profit Before Tax 17.99 65.2 9.13 4.19 3.52
Tax 5.46 2.8 1.13 2.91 0.98
Profit After Tax 12.54 62.4 8 1.28 2.54
Adjusted EPS (Rs) 1.39 6.91 0.89 0.14 0.28

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 1537.44 1691.93 1857.57 1979 1854.5
Total Expenditure 1398.39 1487.48 1698.34 1902.37 1771.77
Operating Profit 139.04 204.46 159.23 76.63 82.72
Other Income 114.61 93.07 117.09 123.49 99.82
Interest 54.09 66.84 65.34 74.24 138.68
Depreciation 83 94.24 99.34 104.37 93.62
Exceptional Items -3.52 0 0 0 -15
Profit Before Tax 113.03 136.45 111.64 21.51 -64.76
Tax -1.38 16.17 33.4 -158.68 -69.44
Net Profit 110.37 120.28 78.24 180.19 4.68
Adjusted EPS (Rs.) 12.78 13.43 8.72 20.07 0.52

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 89.55 89.57 89.68 89.79 90.3
Total Reserves 3167.25 3069.22 3158.38 3316.89 3364.75
Borrowings 0.15 0 147.54 124.7 284.74
Other N/C liabilities -63.27 -37.31 159.89 -16.42 -12.12
Current liabilities 1388.99 1454.95 1590.64 1841.32 1796.83
Total Liabilities 4582.68 4576.42 5146.12 5356.28 5524.5
Assets
Net Block 496.73 578.35 576.66 604.09 584.3
Capital WIP 72.56 89.47 81.36 30.45 15.79
Intangible WIP 49.9 22.78 29.31 25.26 39.59
Investments 1994.59 2170.55 2394.65 2399.76 2491.77
Loans & Advances 225.85 237.42 247.33 304.95 245.47
Other N/C Assets 79.46 83.82 72.96 16.51 21.18
Current Assets 1663.59 1394.03 1743.86 1975.25 2126.4
Total Assets 4582.68 4576.42 5146.12 5356.28 5524.5
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 108.33 136.45 111.64 21.51 -64.76
Adjustment 90.19 130.28 114.15 75.17 172.87
Changes in Assets & Liabilities -121.04 -96.91 -109.81 -400.77 33.81
Tax Paid -37.52 -32.18 166.79 21.41 99.82
Operating Cash Flow 39.97 137.64 282.76 -282.69 241.74
Investing Cash Flow -166.06 62.83 -275.64 18.78 -182.58
Financing Cash Flow 123.26 -203.56 -48.64 250.73 10.82
Net Cash Flow -2.83 -3.09 -41.52 -13.18 69.98

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 30.89 28.27 28.07 27.78 27.39
aditya arun kumar 0.03 0.06 0.06 0.06 0.06
agraganya private trust - - 0.33 0.33 0.33
ambemata securities 0.53 0.53 0.53 0.53 0.52
anuradha k r 0.01 0.01 0.01 0.01 0.01
arun kumar pillai 2.04 2.15 2.15 2.15 2.11
hemalatha pillai 0.07 0.07 0.07 0.07 0.07
k r lakshmi 0.14 0.14 0.14 0.14 0.14
k r ravishankar 1.39 1.39 1.39 1.39 1.37
karuna business solutions... 1.86 1.86 1.86 1.86 3.51
padmakumar karunakaran pi... 0.21 0.21 0.21 0.21 0.20
pronomz ventures llp 18.45 18.91 18.91 18.90 17.18
rajitha gopalakrishnan 0.07 0.07 0.07 0.07 0.07
sajitha pillai 0.11 0.11 0.11 0.11 0.10
shasun enterprises llp - - 0.91 0.63 0.53
shasun leasing and financ... 1.11 1.11 1.11 1.11 0.98
vineetha mohanakumar pill... 0.21 0.21 0.21 0.21 0.21
abusha investment & manan... 0.20 0.20 - - -
agraganya private trust(t... 0.33 0.33 - - -
shasun enterprises llp(fo... 0.91 0.91 - - -
abhaya kumar s 0.06 - - - -
chaitanya d 0.07 - - - -
gayatri nair 0.04 - - - -
jatin v 0.51 - - - -
jitesh d 0.03 - - - -
lakshmi gopalakrishnan 0.06 - - - -
leela v 0.46 - - - -
monisha nitin 0.17 - - - -
nitin kumar v 0.58 - - - -
pooja srisrimal 0.10 - - - -
purushothaman pillai g 0.04 - - - -
rahul nair 0.02 - - - -
rupali jatin 0.21 - - - -
s abhaya kumar huf 0.09 - - - -
sajjan d 0.20 - - - -
suchi chaitanya srisrimal... 0.10 - - - -
taru mardia 0.02 - - - -
vibha srisrimal 0.02 - - - -
vimal kumar s - (huf) 0.13 - - - -
vimal kumar s 0.32 - - - -
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 69.11 71.73 71.93 72.22 72.61
aditya birla sun life tru... 6.29 5.78 6.10 5.86 5.45
bnp paribas financial mar... - - - - 1.14
investor education and pr... - - - 0.11 0.15
life insurance corporatio... 4.94 4.88 4.22 4.22 4.15
morgan stanley asia (sing... - - - 1.06 1.08
mukul mahavir agrawal - - - - 1.52
oman india joint investme... 1.12 1.12 1.12 1.12 1.10
quant mutual fund - quant... - - 5.51 5.51 5.42
route one fund i, l.p. 2.79 2.64 2.64 2.64 2.59
route one offshore master... 4.60 4.74 4.74 4.74 4.65
satpal khattar 1.73 1.73 1.73 1.73 1.70
sbi long term equity fund... 2.24 2.24 2.24 2.24 2.14
capri global holdings pri... - - 1.33 1.33 -
investor education and pr... 0.11 0.11 0.11 - -
bnp paribas arbitrage 1.33 1.33 - - -
quant mutual fund - quant... - 3.12 - - -
capri global advisory ser... 1.33 - - - -
quant mutual fund - quant... 3.12 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Strides Pharma Science informs about press release9 Apr 2024, 9:49AM Strides Pharma Science’s arm gets USFDA’s approval for Fluoxetine Tabs9 Apr 2024, 9:27AM Strides Pharma Science informs about company update 6 Apr 2024, 3:13PM USFDA completes cGMP inspection at Chennai formulations facility of Strides Pharma Science’s arm6 Apr 2024, 3:02PM Strides Pharma Science informs about completion of inspection6 Apr 2024, 1:59PM Strides Pharma Science informs about disclosure 21 Mar 2024, 12:05PM Strides Pharma Science’s arm receives USFDA’s approval for Gabapentin Tablets5 Mar 2024, 3:41PM Strides Pharma Scien - Quaterly Results30 Jan 2024, 1:16PM Strides Pharma Scien - Quaterly Results30 Jan 2024, 1:16PM Strides Pharma Scien - Quaterly Results30 Jan 2024, 1:16PM Strides Pharma Science’s arm receives USFDA’s approval for Pregabalin Capsules27 Jan 2024, 4:16PM Strides Pharma Science’s arm acquires additional stake in Neviton Softech6 Jan 2024, 2:15PM Strides Pharma Science to invest in AMP-6, AMP-82 Jan 2024, 2:42PM Strides Pharma Science informs about updates23 Dec 2023, 11:26AM Strides Pharma Science informs about disclosure21 Dec 2023, 1:02PM Strides Pharma Science informs about press release23 Nov 2023, 10:17AM Strides Pharma Science’s arm gets USFDA’s nod for Generic Suprep Bowel Prep Kit23 Nov 2023, 9:24AM Strides Pharma Science informs about press release21 Nov 2023, 12:20PM Strides Pharma Science’s arm gets USFDA’s nod for Levetiracetam Oral Solution21 Nov 2023, 11:29AM Strides Pharma Scien - Quaterly Results30 Oct 2023, 12:16PM Strides Pharma Scien - Quaterly Results30 Oct 2023, 12:16PM Strides Pharma Scien - Quaterly Results30 Oct 2023, 12:16PM Strides Pharma’s arm to sell manufacturing facility for $15 million30 Oct 2023, 11:30AM Strides Pharma Science informs about analyst meet25 Oct 2023, 11:32AM Strides Pharma Science informs about disclosure 12 Oct 2023, 2:57PM Strides Pharma Science’s arm gets USFDA’s approval for EET tablets4 Oct 2023, 5:20PM Strides Pharma Science to demerge CDMO, soft gelatin biz into separate entity 26 Sep 2023, 3:59PM Strides Pharma Science informs about investor call25 Sep 2023, 11:59AM Strides Pharma Science’s arm gets USFDA’s approval for Icosapent Ethyl Capsules25 Sep 2023, 11:56AM Strides Pharma’s arm gets USFDA’s tentative nod for Dolutegravir/ Lamivudine/ Tenofovir Disproxil Fumurate tablets15 Sep 2023, 4:00PM Strides Pharma Science’s arm gets tentative approval for Dolutegravir 50mg tablets14 Sep 2023, 6:18PM Strides Pharma Science’s arm gets USFDA’s approval for Sevelamer Carbonate for Oral Suspension9 Sep 2023, 2:23PM Strides Pharma Science informs about disclosure 7 Sep 2023, 12:28PM Strides Pharma Science gets nod to acquire 100% stake in Strides Pharma Services7 Sep 2023, 11:14AM Strides Pharma Science’s arm gets USFDA’s nod for Mycophenolate Mofetil for Oral Suspension30 Aug 2023, 12:12PM Strides Pharma Science informs about press release2 Aug 2023, 1:22PM Strides Pharma Science submits unaudited financial results 2 Aug 2023, 12:27PM Strides Pharma Scien - Quaterly Results2 Aug 2023, 11:51AM Strides Pharma Scien - Quaterly Results2 Aug 2023, 11:51AM Strides Pharma Scien - Quaterly Results2 Aug 2023, 11:51AM Strides Pharma Science informs about details of loss of certificate18 Jul 2023, 1:09PM Strides Pharma Science’s biologics arm enters into binding term sheet with Syngene International 5 Jul 2023, 9:40AM Strides Pharma Science informs about disclosure 15 Jun 2023, 10:43AM Strides Pharma Science informs about earnings call transcript1 Jun 2023, 3:09PM Strides Pharma Scien - Quaterly Results25 May 2023, 2:20PM Strides Pharma Scien - Quaterly Results25 May 2023, 2:20PM Strides Pharma Science India informs about updates 19 May 2023, 9:38AM Strides Pharma Science gets EIR from USFDA for Puducherry manufacturing facility19 May 2023, 9:14AM Strides Pharma Science informs about press release3 May 2023, 9:39AM Strides Pharma Science enters into strategic partnership with Orbicular3 May 2023, 9:26AM

Strides Pharma Scien Stock Price Analysis and Quick Research Report. Is Strides Pharma Scien an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Strides Pharma Scien and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Strides Pharma Scien cash from the operating activity was Rs 241.74 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Strides Pharma Scien has a Debt to Equity ratio of 0.3927 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Strides Pharma Scien , the EPS growth was -97.4162460072654 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Strides Pharma Scien has OPM of 4.46067287284524 % which is a bad sign for profitability.
     
  • ROE: Strides Pharma Scien have a poor ROE of 0.136903286833878 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Strides Pharma Scien is Rs 839.5. One can use valuation calculators of ticker to know if Strides Pharma Scien share price is undervalued or overvalued.
Last Updated on:
Brief about Strides Pharma Scien

Strides Pharma Science Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Strides Pharma Science Ltd. is an Indian multinational pharmaceutical company headquartered in Bangalore, India. The company was founded in 1990 and has since then been a leading player in the global pharmaceutical market. Strides Pharma Science Ltd. has a presence in over 100 countries worldwide and is committed to providing high-quality, affordable healthcare solutions to people around the globe.

Strides Pharma Science Ltd. Share Price

The share price of Strides Pharma Science Ltd. is a key indicator of the company's financial performance. Investors who are looking to invest in the company can keep an eye on the share price and monitor any fluctuations. The share price can also be used to determine the company's market capitalization and valuation, which can be useful in making investment decisions.

Strides Pharma Science Ltd. Balance Sheet

The balance sheet of Strides Pharma Science Ltd. provides a snapshot of the company's financial position at a particular point in time. Investors can use the balance sheet to assess the company's liquidity, solvency, and overall financial health. Our website provides pre-built screening tools that can be used to analyze the balance sheet using various methods such as DCF Analysis, BVPS Analysis, Earnings multiple approach and DuPont analysis.

Strides Pharma Science Ltd. Annual Report

The annual report of Strides Pharma Science Ltd. provides a comprehensive overview of the company's financial performance over the past year. Investors can use the annual report to assess the company's revenue, profits, and expenses. Our website provides the annual report as a downloadable document, which can be accessed by investors and analysts.

Strides Pharma Science Ltd. Dividend

Dividends are an important aspect of any investment. They are a way for shareholders to earn a return on their investment in a company. Strides Pharma Science Ltd. has a history of paying dividends to its shareholders. Investors can track the dividend history of the company on our website and stay updated on any changes.

Strides Pharma Science Ltd. Quarterly Result

The quarterly result of Strides Pharma Science Ltd. provides a detailed analysis of the company's financial performance for a particular quarter. Investors can use the quarterly result to assess the company's revenue, profits, and expenses. Our website provides pre-built screening tools that can be used to analyze the quarterly result using various methods.

Strides Pharma Science Ltd. Stock Price

The stock price of Strides Pharma Science Ltd. is a key indicator of the company's financial performance. Investors can track the stock price on our website and stay updated on any changes. The stock price can also be used to determine the company's market capitalization and valuation, which can be useful in making investment decisions.

Strides Pharma Science Ltd. Price Chart

Price charts are a useful tool for investors who are looking to track the stock price of a company over time. Our website provides price charts for Strides Pharma Science Ltd. that allow investors to analyze the stock price trend over a period of time. The price chart can be used to identify patterns and trends that can be useful in making investment decisions.

Strides Pharma Science Ltd. News

Our website provides the latest news and updates about Strides Pharma Science Ltd. Investors can stay updated on any new developments in the company by regularly checking our news section. The news can provide useful insights into the company's future plans and strategies.

Strides Pharma Science Ltd. Concall Transcripts

Concall transcripts provide a detailed record of the company's conference calls with analysts and investors. Our website provides the concall transcripts for Strides Pharma Science Ltd. as downloadable documents. Investors can use the concall transcripts to gain insights into the company's future plans and strategies.

Strides Pharma Science Ltd. Investor Presentations

Investor presentations provide a detailed overview of the company's financial performance and future plans. Our website provides the investor presentations of Strides Pharma Science Ltd. as downloadable documents. Investors can use the investor presentations to analyze the company's financial health and future prospects.

Strides Pharma Science Ltd. Promoters

Promoters are individuals or entities who hold a significant stake in the company and play an important role in its management. Strides Pharma Science Ltd. has several prominent promoters who have played a key role in the company's growth over the years. Our website provides information about the company's promoters, including their background and their role in the company.

Strides Pharma Science Ltd. Shareholders

Shareholders are individuals or entities who hold shares in the company. Strides Pharma Science Ltd. has a wide range of shareholders, including institutional investors, retail investors, and high net worth individuals. Our website provides information about the company's major shareholders and their stake in the company.

Premium Features

Our website provides several premium features that can be used to analyze the financial performance of Strides Pharma Science Ltd. These features include DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. Investors can use these tools to gain a deeper understanding of the company's financial health and future prospects.

Note: Kindly note that the above content is strictly just for informative purposes and does not attempt to recommend any specific actions or decisions for the investors. We always advise investors to carry out thorough research and consult with financial experts before making any investment decisions.

Read More
X